







Using LLMs for data- and knowledge management in radiation oncology Fabio Dennstädt

# Projects of the ISROI




> Adv Radiat Oncol. 2023 Nov 4;9(3):101400. doi: 10.1016/j.adro.2023.101400. eCollection 2024 Mar.


## Exploring Capabilities of Large Language Models such as ChatGPT in Radiation Oncology

> Adv Radiat Oncol. 2023 Nov 4;9(3):101400. doi: 10.1016/j.adro.2023.101400. eCollection 2024 Mar.

# Exploring Capabilities of Large Language Models such as ChatGPT in Radiation Oncology




## Exploring Capabilities of Large Language Models such as ChatGPT in Radiation Oncology



> Adv Radiat Oncol. 2023 Nov 4;9(3):101400. doi: 10.1016/j.adro.2023.101400. eCollection 2024 Mar.

## Exploring Capabilities of Large Language Models such as ChatGPT in Radiation Oncology


Fabio Dennstädt <sup>1</sup>, Janna Hastings <sup>2</sup> <sup>3</sup>, Paul Martin Putora <sup>1</sup> <sup>4</sup>, Erwin Vu <sup>1</sup>, Galina F Fischer <sup>1</sup>, Krisztian Süveg <sup>1</sup>, Markus Glatzer <sup>1</sup>, Elena Riggenbach <sup>4</sup>, Hông-Linh Hà <sup>4</sup>, Nikola Cihoric <sup>4</sup>






**Non-Knowledge-based CDSS** 

## Exploring Capabilities of Large Language Models such as ChatGPT in Radiation Oncology





#### Example of "good answer"

"A patient with limited disease small-cell lung cancer had chemotherapy with concurrent radiotherapy for 6 weeks. After 4 weeks of the treatment, he is beginning to develop symptoms of pain during swallowing (VAS 6/10), which he describes as burning. He also suffers from impaired swallowing, which is why he reduced eating. What is the most likely reason for the symptoms and how could you help the patient?".

### Example of "good answer"

"A patient with limited disease small-cell lung cancer had chemotherapy with concurrent radiotherapy for 6 weeks. After 4 weeks of the treatment, he is beginning to develop symptoms of pain during swallowing (VAS 6/10), which he describes as burning. He also suffers from impaired swallowing. which is why he reduced eating. What is the most likely reason for the symptoms and how could you help the patient?".

"The most likely reason for the patient's symptoms of pain during swallowing and impaired swallowing is radiation-induced esophagitis, which is a common side effect of concurrent chemoradiotherapy for lung cancer. The symptoms can be due to inflammation and injury of the esophageal mucosa caused by the radiation.

To help the patient, the following measures can be taken:

- 1. Pain management: Over-the-counter pain relievers or prescription pain medication can be used to manage the pain.
- 2. Diet modification: Soft, bland foods and frequent small meals can help alleviate symptoms and improve swallowing. Avoiding spicy and acidic foods can also help.
- 3. Mouth care: Good oral hygiene, such as regular mouth rinses and gargles, can help to soothe the throat and prevent infections.
- 4. Lubricating agents: Using agents such as honey, glycerin, or saliva substitutes can help to lubricate the throat and improve swallowing.

It is important to consult a medical professional for proper evaluation and management of the patient's symptoms, as the above measures may not be sufficient to alleviate symptoms in all cases. Additionally, if the symptoms persist or worsen, further investigations such as endoscopy may be necessary to rule out other causes."

"The most likely reason for the patient's symptoms of pain during swallowing and impaired swallowing is radiation-induced esophagitis which is a common side effect of concurrent chemoradiotherapy for lung cancer. The symptoms can be due to inflammation and injury of the esophageal mucosa caused by the radiation.

To help the patient, the following measures can be taken:

- 1. Pain management: Over-the-counter pain relievers or prescription pain medication can be used to manage the pain.
- 2. Diet modification: Soft, bland foods and frequent small meals can help alleviate symptoms and improve swallowing. Avoiding spicy and acidic foods can also help.
- 3. Mouth care: Good oral hygiene, such as regular mouth rinses and gargles, can help to soothe the throat and prevent infections.
- 4. Lubricating agents: Using agents such as honey, glycerin, or saliva substitutes can help to lubricate the throat and improve swallowing.

It is important to consult a medical professional for proper evaluation and management of the patient's symptoms, as the above measures may not be sufficient to alleviate symptoms in all cases. Additionally, if the symptoms persist or worsen, further investigations such as endoscopy may be necessary to rule out other causes."

"The most likely reason for the patient's symptoms of pain during swallowing and impaired swallowing is radiation-induced esophagitis which is a common side effect of concurrent chemoradiotherapy for lung cancer. The symptoms can be due to inflammation and injury of the esophageal mucosa caused by the radiation.



To help the patient, the following measures can be taken:

1. Pain management: Over-the-counter pain relievers or prescription pain medication can be used to manage the pain.



2. Diet modification: Soft, bland foods and frequent small meals can help alleviate symptoms and improve swallowing. Avoiding spicy and acidic foods can also help.



3. Mouth care: Good oral hygiene, such as regular mouth rinses and gargles, can help to soothe the throat and prevent infections.



4. Lubricating agents: Using agents such as honey, glycerin, or saliva substitutes can help to lubricate the throat and improve swallowing.



It is important to consult a medical professional for proper evaluation and management of the patient's symptoms, as the above measures may not be sufficient to alleviate symptoms in all cases. Additionally, if the symptoms persist or worsen, further investigations such as endoscopy may be necessary to rule out other causes."

"The most likely reason for the patient's symptoms of pain during swallowing and impaired swallowing is radiation-induced esophagitis which is a common side effect of concurrent chemoradiotherapy for lung cancer. The symptoms can be due to inflammation and injury of the esophageal mucosa caused by the radiation.



To help the patient, the following measures can be taken:

1. Pain management: Over-the-counter pain relievers or prescription pain medication can be used to manage the pain.



2. Diet modification: Soft, bland foods and frequent small meals can help alleviate symptoms and improve swallowing. Avoiding spicy and acidic foods can also help.



3. Mouth care: Good oral hygiene, such as regular mouth rinses and gargles, can help to soothe the throat and prevent infections.



4. Lubricating agents: Using agents such as honey, glycerin, or saliva substitutes can help to lubricate the throat and improve swallowing.




It is important to consult a medical professional for proper evaluation and management of the patient's symptoms, as the above measures may not be sufficient to alleviate symptoms in all cases. Additionally, if the symptoms persist or worsen, further investigations such as endoscopy may be necessary to rule out other causes."

Score of 5.00 regarding both correctness and usefulness


• "What is 20x3Gy in EQD2 based on the linear-quadratic model using an  $\alpha/\beta$ =2?".

• "What is 20x3Gy in EQD2 based on the linear-quadratic model using an  $\alpha/\beta=2$ ?".

In this case the correct answer would be EQD2 = 75 Gy.



• "What is 20x3Gy in EQD2 based on the linear-quadratic model using an  $\alpha/\beta=2$ ?".




In this case the correct answer would be EQD2 = 75 Gy.

"The equivalent dose in 2 Gy fractions (EQD2) can be calculated using the linear-quadratic model and an  $\alpha/\beta$  of 2 as follows:

$$EQD2 = 20 \times 3Gy * (2 + (2/\alpha/\beta)) = 20 \times 3Gy * (2 + (2/2)) = 20 \times 3Gy * 4 = 240 Gy$$

So, the EQD2 for 20 fractions of 3 Gy each with an  $\alpha/\beta$  of 2 is 240 Gy."

• "What is 20x3Gy in EQD2 based on the linear-quadratic model using an  $\alpha/\beta=2$ ?".



 $\alpha D$ 

 $\beta D^2$ 

Radiation dose [Gy]

In this case the correct answer would be EQD2 = 75 Gy.

"The equivalent dose in 2 Gy fractions (EQD2) can be calculated using the linear-quadratic model and an  $\alpha/\beta$  of 2 as follows:

$$EQD2 = 20 \times 3Gy * (2 + (2/\alpha/\beta)) = 20 \times 3Gy * (2 + (2/2)) = 20 \times 3Gy * 4 = 240 Gy$$

So, the EQD2 for 20 fractions of 3 Gy each with an  $\alpha/\beta$  of 2 is 240 Gy."



→ Overall mixed result with good performance on some of the questions.

→ Overall mixed result with good performance on some of the questions.


Multicentric follow-up study with medically optimized LLM in colloaboration with task groupd "digitization and AI" of DEGRO ongoing.




Diagnosis lists (free text)

"Breast cancer left side at 12.00 NST cT1c cN0 G2 R0 ER 100%

- Screening detected
- 20.09.22 segmentectomy left breast
- Histology: 15 mm breast cancer NST, pN0 (sn) (0/2)





CDE	Correct values given by LLM
Age	100%
Laterality	96%
Menopausal Status	99%
molecular Type	99%
Laterality	96%
L-Status	96%
progesteron receptor status	95%
estrogen receptor status	95%
R-Status	94%
•••	

• 31 different CDEs

CDE	Correct values given by LLM
Age	100%
Laterality	96%
Menopausal Status	99%
molecular Type	99%
Laterality	96%
L-Status	96%
progesteron receptor status	95%
estrogen receptor status	95%
R-Status	94%
•••	

- 31 different CDEs
- 7 >= 95% performance

CDE	Correct values given by LLM
Age	100%
Laterality	96%
Menopausal Status	99%
molecular Type	99%
Laterality	96%
L-Status	96%
progesteron receptor status	95%
estrogen receptor status	95%
R-Status	94%
•••	

- 31 different CDEs
- 7 >= 95% performance
- 13 >=90% performance

CDE	Correct values given by LLM
Age	100%
Laterality	96%
Menopausal Status	99%
molecular Type	99%
Laterality	96%
L-Status	96%
progesteron receptor status	95%
estrogen receptor status	95%
R-Status	94%
•••	

• Smart Radiology Goes Digital



• Smart Radiology Goes Digital



Development of a software system to automate extraction and transfer of data along the care path of breast cancer patients, including the domains of radiology, pathology and radiation therapy

Smart Radiology Goes Digital



Development of a software system to automate extraction and transfer of data along the care path of breast cancer patients, including the domains of radiology, pathology and radiation therapy

 Collaboration between academic and industry partners, funded by Innosuisse

















Breast cancer patient





Radiology reports





Tumor board



Breast cancer patient

























... results will be published towards end of 2024


Extraction of CDE values using LLMs
Synoptic Report







#### Instruction

On a scale from 1 (very low probability) to 5 (very high probability), how would you consider the relevance of the following scientific publication to be included in a systematic literature review based on the inclusion criteria and based on title and abstract?







Sensitivity (=Recall) / Specificity in citation screening on 10 different biomedical topics

- 94.48%/31.78% for FlanT5 model
- 97.58%/19.12% for OpenHermes-NeuralChat model
- 81.93%/75.19% for Mixtral model
- 97.58%/38.34% for the Platypus 2 model



521 publications

36 relevant


485 irrelevant

(as determined by humans)



521 publications

36 relevant 485 irrelevant (as determined by humans)



521 publications

36 relevant


485 irrelevant


(as determined by humans)




521 publications


36 relevant 485 irrelevant (as determined by humans)







→ Exclusion of 58 % irrelevant publications without missing a relevant one



→ Exclusion of 58 % irrelevant publications without missing a relevant one

Manuscript under review


What are other people doing?

• LLM developed by Google, aligned to the medical domain

- LLM developed by Google, aligned to the medical domain
- First LLM to surpass the mark on USMLE style questions, published in December 2022


- LLM developed by Google, aligned to the medical domain
- First LLM to surpass the mark on USMLE style questions, published in December 2022
- 60% pass mark, Med-PaLM achieved 67%

- LLM developed by Google, aligned to the medical domain
- First LLM to surpass the mark on USMLE style questions, published in December 2022
- 60% pass mark, Med-PaLM achieved 67%



Lay assessment of helpfulness of answers

- LLM developed by Google, aligned to the medical domain
- First LLM to surpass the mark on USMLE style questions, published in December 2022
- 60% pass mark, Med-PaLM achieved 67%



Lay assessment of helpfulness of answers

• successor of Med-PaLM, results published in March 2023

- successor of Med-PaLM, results published in March 2023
- achieved 85% on USMLE questions (+18% in 4 months)

- successor of Med-PaLM, results published in March 2023
- achieved 85% on USMLE questions (+18% in 4 months)
- reported to answer questions at an "expert doctor level"





T A	Model	A	Average [1] 🔺	MedMCQA ▲	MedQA ▲	MMLU Anatomy A	MMLU Clinical Knowledge 🔺	MMLU College Biology
<b>\rightarrow</b>	bongbongs/NewMes-v6		87.13	70.91	76.36	94.81	94.72	96.53
<b>\rightarrow</b>	aaditya/OpenBioLLMLlama-70B		86.06	74.01	78.16	83.9	92.93	93.83
<b>\</b>	Jayant9928/orpo_med_v7		84.42	58.95	69.36	86.67	95.47	94.44
<b>\rightarrow</b>	johnsnowlabs/JSL-MedLlama-3-8B-v4.0		84.12	58.74	61.74	89.63	94.72	96.53
	Med-PaLM 2 (5 Shots)		84.09	71.3	79.7	77.8	88.3	94.4
<b>\</b>	<pre>Jayant9928/orpo_med_v6</pre>		83.46	59.02	62.92	88.15	94.34	93.75
<b>\rightarrow</b>	ProbeMedicalYonseiMAILab/medllama3-v16.2		83.1	73.06	79.18	80	84.91	91.67
<b>\</b>	bongbongs/NewMes-v5.2		83.1	73.06	79.18	80	84.91	91.67
	GPT-4		82.97	69.5	78.8	80	86.4	95.1
<b>\</b>	<pre>Jayant9928/orpo_med_v5</pre>		82.83	59.77	63.32	88.89	93.58	91.67
<b>\rightarrow</b>	ProbeMedicalYonseiMAILab/medllama3-v16.1		82.12	70.81	78.32	79.26	86.79	90.28



T 🔺	Model	A	Average 1	MedMCQA A	MedQA A	MMLU Anatomy A	MMLU Clinical Knowledge A	MMLU College Biology
<b>\</b>	bongbongs/NewMes-v6		87.13	70.91	76.36	94.81	94.72	96.53
<b>\Q</b>	aaditya/OpenBioLLMLlama-70B		86.06	74.01	78.16	83.9	92.93	93.83
<b>\rightarrow</b>	Jayant9928/orpo_med_v7		84.42	58.95	69.36	86.67	95.47	94.44
<b>\Q</b>	johnsnowlabs/JSL-MedLlama-3-8B-v4.0		84.12	58.74	61.74	89.63	94.72	96.53
	Med-PaLM 2 (5 Shots)		84.09	71.3	79.7	77.8	88.3	94.4
<b>\Q</b>	Jayant9928/orpo_med_v6		83.46	59.02	62.92	88.15	94.34	93.75
<b>\Q</b>	ProbeMedicalYonseiMAILab/medllama3-v16.2		83.1	73.06	79.18	80	84.91	91.67
<b>\Q</b>	bongbongs/NewMes-v5.2		83.1	73.06	79.18	80	84.91	91.67
	GPT-4		82.97	69.5	78.8	80	86.4	95.1
<b>\</b>	Jayant9928/orpo_med_v5		82.83	59.77	63.32	88.89	93.58	91.67
<b>\rightarrow</b>	ProbeMedicalYonseiMAILab/medllama3-v16.1		82.12	70.81	78.32	79.26	86.79	90.28



T 🔺	Model	Average 🚺 🔺	MedMCQA ▲	MedQA ▲	MMLU Anatomy A	MMLU Clinical Knowledge 🔺	MMLU College Biology	
<b>\Q</b>	bongbongs/NewMes-v6	87.13	70.91	76.36	94.81	94.72	96.53	
<b>\</b>	aaditya/OpenBioLLMLlama-70B	86.06	74.01	78.16	83.9	92.93	93.83	
<b>\rightarrow</b>	Jayant9928/orpo_med_v7	84.42	58.95	69.36	86.67	95.47	94.44	
<b>\rightarrow</b>	johnsnowlabs/JSL-MedLlama-3-8B-v4.0	84.12	58.74	61.74	89.63	94.72	96.53	
	Med-PaLM 2 (5 Shots)	84.09	71.3	79.7	77.8	88.3	94.4	
<b>\Q</b>	<pre>Jayant9928/orpo_med_v6</pre>	83.46	59.02	62.92	88.15	94.34	93.75	
<b>\Q</b>	ProbeMedicalYonseiMAILab/medllama3-v16.2	83.1	73.06	79.18	80	84.91	91.67	
<b>\Q</b>	bongbongs/NewMes-v5.2	83.1	73.06	79.18	80	84.91	91.67	
	<u>GPT-4</u>	82.97	69.5	78.8	80	86.4	95.1	
<b>\rightarrow</b>	<pre>Jayant9928/orpo_med_v5</pre>	82.83	59.77	63.32	88.89	93.58	91.67	
<b>\Q</b>	ProbeMedicalYonseiMAILab/medllama3-v16.1	82.12	70.81	78.32	79.26	86.79	90.28	



### LLaVA-Med

#### Visual input example, Biomedical image:



### LLaVA-Med

#### Visual input example, Biomedical image:



User

What is this image about?

#### LLaVA-Med


#### Visual input example, Biomedical image:



User LLaVA-Med

What is this image about?

The image is a coronal view of a computed tomography (CT) scan of the abdomen and pelvis. It provides a detailed view of the internal organs and structures within the abdominal and pelvic cavities.





On June 30, 2022, what will be the state-of-the-art few-shot or transfer accuracy on the Massive Multitask Language Understanding dataset?

Forecast: 57.1 %



71 forecasters Start: 2021-07-24 End: 2021-09-29 From MMLU\_college\_medicine:

Acute Myeloid Leukemia is a malignant cancer in which myeloid progenitor cells become rapidly dividing and retain their semi-stem cell state. Under normal circumstances, which of the following cell types would arise from this stem cell?

#### From MMLU\_college\_medicine:

Acute Myeloid Leukemia is a malignant cancer in which myeloid progenitor cells become rapidly dividing and retain their semi-stem cell state. Under normal circumstances, which of the following cell types would arise from this stem cell?

A: NK cell

B: Platelet

C: T cell

D: Lymphoid progenitor


On June 30, 2022, what will be the state-of-the-art few-shot or transfer accuracy on the Massive Multitask Language Understanding dataset?

Crowd Forecast History

Forecast: **57.1** %

More Info

News




71 forecasters Start: 2021-07-24 End: 2021-09-29


On June 30, 2022, what will be the state-of-the-art few-shot or transfer accuracy on the Massive Multitask Language Understanding dataset?

Forecast: 57.1 %

More Info
News

71 forecasters Start: 2021-07-24 End: 2021-09-29





→ Underprediction

 LLMs are very powerful for different tasks regarding data- and knowledge management in radiation therapy, as well as general medicine

- LLMs are very powerful for different tasks regarding data- and knowledge management in radiation therapy, as well as general medicine
- Many groups are working on many different use cases

- LLMs are very powerful for different tasks regarding data- and knowledge management in radiation therapy, as well as general medicine
- Many groups are working on many different use cases
- The progress in the field is very rapid

Thank you for your attention.